Related Experiment Video

Updated: Jun 16, 2026

Precise Visualization of Insulin Receptors A and B in Murine Brain with an RNA In Situ Hybridization Assay
08:34

Precise Visualization of Insulin Receptors A and B in Murine Brain with an RNA In Situ Hybridization Assay

Published on: July 15, 2025

An overview of currently available anti-insulin-like growth factor I receptor antibodies

Yu Kusada1, Yoko Fujita-Yamaguchi

  • 1Department of Applied Biochemistry, Tokai University School of Engineering, Hiratsuka, Kanagawa, Japan.

Bioscience Trends
|January 28, 2010
PubMed

Insights

Anti-insulin-like growth factor I receptor (IGFIR) antibodies are promising for cancer therapy. This review details available antibodies, their binding sites, and their effectiveness in inhibiting cancer growth.

Area of Science:

  • Oncology
  • Molecular Biology
  • Immunotherapy

Background:

  • The insulin-like growth factor I receptor (IGFIR) has emerged as a significant target in molecular cancer therapy over the past two decades.
  • Various molecular strategies targeting IGFIR have been developed and assessed in experimental settings.

Purpose of the Study:

  • To review currently available anti-IGFIR antibodies.
  • To emphasize epitope mapping of these antibodies.
  • To discuss anti-IGFIR antibody-induced cancer growth inhibition.

Main Methods:

  • Literature review of studies on anti-IGFIR antibodies.
  • Analysis of epitope mapping data for selected antibodies.
  • Evaluation of experimental data on cancer growth inhibition by anti-IGFIR antibodies.

Main Results:

  • Several anti-IGFIR antibodies have been developed and evaluated for therapeutic potential.
  • Epitope mapping provides insights into antibody-target interactions.
  • Anti-IGFIR antibodies demonstrate efficacy in inhibiting cancer growth in experimental systems.

Conclusions:

  • Anti-IGFIR antibodies represent a viable therapeutic strategy for cancer.
  • Further research into epitope-specific antibodies may enhance therapeutic outcomes.
  • The therapeutic potential of anti-IGFIR antibodies warrants continued investigation.

More Related Videos

Chemically-blocked Antibody Microarray for Multiplexed High-throughput Profiling of Specific Protein Glycosylation in Complex Samples13:21

Chemically-blocked Antibody Microarray for Multiplexed High-throughput Profiling of Specific Protein Glycosylation in Complex Samples

Published on: May 4, 2012

Related Concept Videos

Insulin: The Receptor and Signaling Pathways01:28

Insulin: The Receptor and Signaling Pathways

Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but this inhibition is released...
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Production of Pharmaceuticals01:30

Production of Pharmaceuticals

Industrial insulin production uses genetically engineered E. coli expressing a proinsulin gene controlled by a tryptophan promoter and containing a methionine linker for later cleavage. The cells also carry ampicillin resistance for selective growth. Seed cultures are stored at −80 °C and production begins by thawing a small amount to inoculate starter cultures, which are progressively scaled to a 50,000-L bioreactor. In the bioreactor, E. coli grow in nutrient-rich media under sterile, tightly...
Antibody Structure01:10

Antibody Structure

Overview
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...
Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...